|Sung-Hee Son||Exec. Officer||N/A||N/A||N/A|
|Se-Nyun Kim||Exec. Officer||N/A||N/A||N/A|
|Hirose Dakashi||Exec. Officer||N/A||N/A||N/A|
|Su-Sung Lee||Exec. Officer||N/A||N/A||N/A|
|So-Jin Ahn||Exec. Officer||N/A||N/A||N/A|
Oscotec Inc., a biotech company, engages in drug discovery for rheumatoid arthritis, leukemia, lung cancer, and periodontal diseases in Korea and internationally. It develops SYK inhibitor that is in Phase I clinical study to treat rheumatoid arthritis and systemic lupus erythematosus; FLT3 inhibitor for the treatment of acute myeloid leukemia; EGFR double mutation inhibitor to treat non-small cell lung cancer; and BT-301, a botanical drug that is in Phase III clinical study for the treatment of periodontal disease. The company's drug development pipeline also includes 4th gen EGFR inhibitor to treat non-small cell lung cancer; FGFR4 inhibitor for the treatment of hepatocellular carcinoma; 2nd gen SYK inhibitor to treat blood cancer; and MELK inhibitor for triple negative breast cancer. It also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; membrane consisting of LysoGide and CollaGuide; and centrifuge, including PRP/PRF centrifuge and PRP reagents. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is headquartered in Seongnam, South Korea.
Oscotec Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.